BRPI0918337A2 - composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e uso - Google Patents
composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e usoInfo
- Publication number
- BRPI0918337A2 BRPI0918337A2 BRPI0918337A BRPI0918337A BRPI0918337A2 BR PI0918337 A2 BRPI0918337 A2 BR PI0918337A2 BR PI0918337 A BRPI0918337 A BR PI0918337A BR PI0918337 A BRPI0918337 A BR PI0918337A BR PI0918337 A2 BRPI0918337 A2 BR PI0918337A2
- Authority
- BR
- Brazil
- Prior art keywords
- platelets
- patient
- exacerbated
- disease
- excess
- Prior art date
Links
- 230000004913 activation Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13947908P | 2008-12-19 | 2008-12-19 | |
| PCT/US2009/068400 WO2010080478A1 (en) | 2008-12-19 | 2009-12-17 | Compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0918337A2 true BRPI0918337A2 (pt) | 2017-05-30 |
Family
ID=42316717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0918337A BRPI0918337A2 (pt) | 2008-12-19 | 2009-12-17 | composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e uso |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8114893B2 (https=) |
| EP (1) | EP2376085B1 (https=) |
| JP (1) | JP5683484B2 (https=) |
| KR (1) | KR101633532B1 (https=) |
| CN (1) | CN102325531B (https=) |
| AU (1) | AU2009335818A1 (https=) |
| BR (1) | BRPI0918337A2 (https=) |
| CA (1) | CA2747161C (https=) |
| CO (1) | CO6390110A2 (https=) |
| CR (1) | CR20110389A (https=) |
| DO (1) | DOP2011000198A (https=) |
| EC (1) | ECSP11011214A (https=) |
| ES (1) | ES2462715T3 (https=) |
| IL (1) | IL213547A0 (https=) |
| MX (1) | MX2011006514A (https=) |
| NZ (1) | NZ593536A (https=) |
| PE (1) | PE20120305A1 (https=) |
| RU (1) | RU2561109C2 (https=) |
| SG (1) | SG172266A1 (https=) |
| WO (1) | WO2010080478A1 (https=) |
| ZA (1) | ZA201104463B (https=) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2951295C (en) | 2007-04-16 | 2020-04-28 | Abbvie Inc. | 7-nonsubstituted indole mcl-1 inhibitors |
| WO2009085216A2 (en) | 2007-12-20 | 2009-07-09 | Squicor | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease |
| WO2010080503A1 (en) * | 2008-12-19 | 2010-07-15 | Genentech, Inc. | Heterocyclic compounds and methods of use |
| NZ593536A (en) | 2008-12-19 | 2013-07-26 | Genentech Inc | Quinoline derivatives and methods of use |
| US10010439B2 (en) | 2010-06-13 | 2018-07-03 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US8628554B2 (en) | 2010-06-13 | 2014-01-14 | Virender K. Sharma | Intragastric device for treating obesity |
| US9526648B2 (en) | 2010-06-13 | 2016-12-27 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| US10420665B2 (en) | 2010-06-13 | 2019-09-24 | W. L. Gore & Associates, Inc. | Intragastric device for treating obesity |
| ES2659763T3 (es) | 2011-02-14 | 2018-03-19 | The Regents Of The University Of Michigan | Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados |
| WO2012177927A1 (en) | 2011-06-21 | 2012-12-27 | Mayo Foundation For Medical Education And Research | Transgenic animals capable of being induced to delete senescent cells |
| TWI571466B (zh) * | 2011-10-14 | 2017-02-21 | 艾伯維有限公司 | 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑 |
| US8940737B2 (en) | 2011-10-14 | 2015-01-27 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| US8889675B2 (en) | 2011-10-14 | 2014-11-18 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| TWI561521B (en) * | 2011-10-14 | 2016-12-11 | Abbvie Inc | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| MX2014007093A (es) | 2011-12-13 | 2014-10-13 | Buck Inst For Res On Aging | Metodos para mejorar terapias medicas. |
| US20150064137A1 (en) | 2012-04-17 | 2015-03-05 | Kythera Biopharmaceuticals, Inc. | Use of engineered viruses to specifically kill senescent cells |
| US9901081B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse for determining the role of senescent cells in cancer |
| US9901080B2 (en) | 2012-08-23 | 2018-02-27 | Buck Institute For Research On Aging | Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells |
| EP2991647B1 (en) | 2013-05-02 | 2019-04-24 | The Regents Of The University Of Michigan | Deuterated amlexanox with improved metabolic stability |
| RU2550346C2 (ru) * | 2013-09-26 | 2015-05-10 | Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" | Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний |
| TN2016000115A1 (en) | 2013-10-25 | 2017-07-05 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors. |
| JP6526023B2 (ja) * | 2014-01-24 | 2019-06-05 | パーデュー、ファーマ、リミテッド、パートナーシップ | ピリジン類及びピリミジン類並びにその使用 |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| IL286427B2 (en) | 2014-01-28 | 2024-08-01 | Mayo Found Medical Education & Res | Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| CN103804367B (zh) * | 2014-02-28 | 2016-09-14 | 天津药物研究院 | 苯并氮杂卓衍生物、其制备方法和用途 |
| EP3125884B1 (en) | 2014-04-04 | 2019-11-06 | The Regents of the University of Michigan | Small molecule inhibitors of mcl-1 and uses thereof |
| EP3139942B1 (en) | 2014-05-05 | 2019-12-18 | Bioventures, Llc | COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS |
| EP3166928B1 (en) * | 2014-07-08 | 2019-04-03 | Dow AgroSciences LLC | Process for the preparation of 3-hydroxypicolinic acids |
| WO2016014625A1 (en) | 2014-07-22 | 2016-01-28 | Board Of Trustees Of The University Of Arkansas | Compositions and methods for selectively depleting senescent cells |
| KR102432970B1 (ko) * | 2014-07-28 | 2022-08-16 | 메르크 파텐트 게엠베하 | 금속 착물 |
| JP6585167B2 (ja) | 2014-10-03 | 2019-10-02 | ノバルティス アーゲー | Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用 |
| CN107207553A (zh) * | 2014-12-09 | 2017-09-26 | 艾伯维公司 | Bcl‑xl抑制性化合物和包括其的抗体药物缀合物 |
| WO2016131100A1 (en) * | 2015-02-18 | 2016-08-25 | The Walter And Eliza Hall Institute Of Medical Research | Methods of treating infectious diseases |
| US10195213B2 (en) | 2015-03-13 | 2019-02-05 | Unity Biotechnology, Inc. | Chemical entities that kill senescent cells for use in treating age-related disease |
| US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| EP3407974A4 (en) | 2016-01-29 | 2019-08-28 | The Regents Of The University Of Michigan | Amlexanox Analogs |
| CA3103604C (en) | 2016-03-28 | 2023-09-26 | Presage Biosciences, Inc. | Pharmaceutical combinations for the treatment of cancer |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| US10779980B2 (en) | 2016-04-27 | 2020-09-22 | Synerz Medical, Inc. | Intragastric device for treating obesity |
| CN108251377B (zh) * | 2018-01-16 | 2021-08-27 | 内蒙古大学 | 利用携带Xist Tale抑制性转录因子R6的R6-MEF制备饲养层细胞的方法 |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| US12084423B2 (en) | 2018-05-18 | 2024-09-10 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| EP3705109A1 (en) | 2019-03-05 | 2020-09-09 | Greenaltech, S.L. | Carotenoids in the treatment of senescence-related diseases |
| CN117304171A (zh) * | 2020-04-20 | 2023-12-29 | 深圳市塔吉瑞生物医药有限公司 | 吡嗪取代的烟酰胺的固体形式及其制备和用途 |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| EP4175644A1 (en) | 2020-07-06 | 2023-05-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| AU2021386367A1 (en) | 2020-11-24 | 2023-06-22 | Les Laboratoires Servier | Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| JP2024505562A (ja) | 2021-02-02 | 2024-02-06 | レス ラボラトイレス セルビエル | 選択的ｂｃｌ－ｘｌ ｐｒｏｔａｃ化合物及び使用の方法 |
| WO2023172958A1 (en) * | 2022-03-08 | 2023-09-14 | Onkosxcel Therapeutics, Llc | Stable formulations of talabostat |
| AR128932A1 (es) * | 2022-03-31 | 2024-06-26 | Beigene Ltd | Inhibidores de bcl-xl |
| AU2023271885A1 (en) | 2022-05-20 | 2024-12-12 | Les Laboratoires Servier | Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof |
| CN119562832A (zh) | 2022-05-20 | 2025-03-04 | 诺华股份有限公司 | Met bcl-xl抑制剂抗体-药物缀合物及其使用方法 |
| US20250387504A1 (en) | 2022-05-20 | 2025-12-25 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
| PY24103486A (es) | 2023-11-22 | 2025-06-06 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
| AR134424A1 (es) | 2023-11-22 | 2026-01-14 | Novartis Ag | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5265280A (en) * | 1975-11-26 | 1977-05-30 | Squibb & Sons Inc | Benzoxadinones and their production |
| DE19929785A1 (de) | 1999-06-29 | 2001-01-04 | Bayer Ag | Tetrahydrochinolinyl-6-methyldihydrothiadiazinon-Derivate und ihre Verwendung |
| KR20020084116A (ko) * | 2000-02-07 | 2002-11-04 | 애보트 게엠베하 운트 콤파니 카게 | 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도 |
| JP4403305B2 (ja) * | 2001-09-03 | 2010-01-27 | 武田薬品工業株式会社 | １，３−ベンゾチアジノン誘導体および用途 |
| CA2459224C (en) | 2001-09-03 | 2012-05-08 | Takeda Chemical Industries, Ltd. | 1,3-benzothiazinone derivatives and the use thereof |
| WO2003051458A1 (en) | 2001-12-14 | 2003-06-26 | Alcon, Inc. | Superoxide dismutase mimics for the treatment of ocular disorders and diseases |
| US8211919B2 (en) | 2005-09-02 | 2012-07-03 | Astellas Pharma Inc. | Amide derivatives as rock inhibitors |
| EP2050749B1 (en) | 2006-08-08 | 2017-11-22 | Chugai Seiyaku Kabushiki Kaisha | Pyrimidine derivative as pi3k inhibitor and use thereof |
| MY162157A (en) | 2007-04-16 | 2017-05-31 | Abbott Lab | Substituted indole mcl-1 inhibitors |
| CA2951295C (en) | 2007-04-16 | 2020-04-28 | Abbvie Inc. | 7-nonsubstituted indole mcl-1 inhibitors |
| EP2193127A4 (en) | 2007-09-27 | 2011-09-14 | Inst Medical W & E Hall | BENZOTHIAZOLE COMPOUNDS |
| US20110172217A1 (en) | 2008-09-05 | 2011-07-14 | Shionogi & Co., Ltd. | Ring-fused morpholine derivative having pi3k-inhibiting activity |
| NZ593536A (en) | 2008-12-19 | 2013-07-26 | Genentech Inc | Quinoline derivatives and methods of use |
| WO2010080503A1 (en) | 2008-12-19 | 2010-07-15 | Genentech, Inc. | Heterocyclic compounds and methods of use |
-
2009
- 2009-12-17 NZ NZ593536A patent/NZ593536A/xx not_active IP Right Cessation
- 2009-12-17 AU AU2009335818A patent/AU2009335818A1/en not_active Abandoned
- 2009-12-17 JP JP2011542420A patent/JP5683484B2/ja active Active
- 2009-12-17 US US12/641,063 patent/US8114893B2/en active Active
- 2009-12-17 CR CR20110389A patent/CR20110389A/es unknown
- 2009-12-17 MX MX2011006514A patent/MX2011006514A/es active IP Right Grant
- 2009-12-17 SG SG2011044922A patent/SG172266A1/en unknown
- 2009-12-17 EP EP09837907.6A patent/EP2376085B1/en active Active
- 2009-12-17 PE PE2011001249A patent/PE20120305A1/es not_active Application Discontinuation
- 2009-12-17 CN CN200980157162.3A patent/CN102325531B/zh active Active
- 2009-12-17 RU RU2011129789/04A patent/RU2561109C2/ru active
- 2009-12-17 KR KR1020117016719A patent/KR101633532B1/ko not_active Expired - Fee Related
- 2009-12-17 WO PCT/US2009/068400 patent/WO2010080478A1/en not_active Ceased
- 2009-12-17 CA CA2747161A patent/CA2747161C/en active Active
- 2009-12-17 BR BRPI0918337A patent/BRPI0918337A2/pt not_active IP Right Cessation
- 2009-12-17 ES ES09837907.6T patent/ES2462715T3/es active Active
-
2011
- 2011-06-14 IL IL213547A patent/IL213547A0/en unknown
- 2011-06-15 ZA ZA2011/04463A patent/ZA201104463B/en unknown
- 2011-06-17 DO DO2011000198A patent/DOP2011000198A/es unknown
- 2011-07-01 CO CO11082793A patent/CO6390110A2/es active IP Right Grant
- 2011-07-18 EC EC2011011214A patent/ECSP11011214A/es unknown
-
2012
- 2012-01-10 US US13/347,364 patent/US8518970B2/en active Active
-
2013
- 2013-06-27 US US13/929,701 patent/US9067928B2/en active Active - Reinstated
Also Published As
| Publication number | Publication date |
|---|---|
| PE20120305A1 (es) | 2012-04-09 |
| US9067928B2 (en) | 2015-06-30 |
| JP2012512887A (ja) | 2012-06-07 |
| ES2462715T3 (es) | 2014-05-26 |
| SG172266A1 (en) | 2011-07-28 |
| CO6390110A2 (es) | 2012-02-29 |
| JP5683484B2 (ja) | 2015-03-11 |
| EP2376085A1 (en) | 2011-10-19 |
| US20120184541A1 (en) | 2012-07-19 |
| HK1161094A1 (en) | 2012-08-24 |
| CR20110389A (es) | 2011-07-13 |
| KR101633532B1 (ko) | 2016-06-24 |
| WO2010080478A1 (en) | 2010-07-15 |
| EP2376085B1 (en) | 2014-02-26 |
| CA2747161C (en) | 2017-07-18 |
| US8518970B2 (en) | 2013-08-27 |
| EP2376085A4 (en) | 2012-08-15 |
| MX2011006514A (es) | 2011-10-11 |
| CN102325531A (zh) | 2012-01-18 |
| IL213547A0 (en) | 2011-07-31 |
| ZA201104463B (en) | 2012-09-26 |
| US20100190782A1 (en) | 2010-07-29 |
| AU2009335818A1 (en) | 2011-07-21 |
| RU2011129789A (ru) | 2013-01-27 |
| US8114893B2 (en) | 2012-02-14 |
| NZ593536A (en) | 2013-07-26 |
| RU2561109C2 (ru) | 2015-08-20 |
| KR20110114581A (ko) | 2011-10-19 |
| ECSP11011214A (es) | 2011-09-30 |
| CN102325531B (zh) | 2014-04-02 |
| CA2747161A1 (en) | 2010-07-15 |
| DOP2011000198A (es) | 2012-08-31 |
| US20140005190A1 (en) | 2014-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0918337A2 (pt) | composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e uso | |
| BRPI0820568A2 (pt) | Composto, composição farmacêutica, uso de um composto ou uma composição farmacêutica, e, método de tratamento de um humano ou animal | |
| BRPI0717697A2 (pt) | composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos | |
| BRPI0715531A2 (pt) | Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto | |
| BRPI0918194A2 (pt) | ''composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação | |
| BRPI0906181A2 (pt) | "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer" | |
| BRPI0915986A2 (pt) | composição, métodos para tratar uma condição, para retardar o início de uma condição, para reduzir o risco em um indivíduo de adquirir uma condição e para alterar a expressão de um ou mais genes em um indivíduo | |
| BRPI0615157A2 (pt) | composto, composição farmacêutica, métodos para inibir a replicação viral em um paciente humano, e para tratar uma infecção viral em um paciente humano, e, uso de um composto | |
| BRPI0909768A2 (pt) | composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto | |
| BRPI0905388A2 (pt) | "composição farmacêutica; compostos e métodos de tratamento de infecção por arenavirus" | |
| BRPI0914387A2 (pt) | sistema de tratamento abdominal, método de tratamento de uma cavidade abdominal aberta, e, método de fabricação de um sistema para tratamento de uma cavidade abdominal de um paciente | |
| BRPI0905687A2 (pt) | "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto" | |
| BRPI1011031A2 (pt) | sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. | |
| BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BRPI0819799A2 (pt) | Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença | |
| BR122019016628B8 (pt) | uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular | |
| BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BRPI1004899A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou distúrbio relacionado a pi3k em um indivíduo necessitando do mesmo, método para tratar uma doença mediada por mtor, método para tratar ambas as doenças mediadas por pi3k e hdac | |
| BRPI0810956A2 (pt) | "composição, método para controlar de modo preventivo ou curativo e uso da composição" | |
| BRPI1011220A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada. | |
| BR112012022211A2 (pt) | composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto | |
| BR112012002246A2 (pt) | composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente | |
| BRPI0814957A2 (pt) | Composto, pró-droga, agente farmacêutico, método para a profilaxia ou tratamento de uma doença, distúrbio ou condição, e, uso do composto. | |
| BRPI1009860A2 (pt) | composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais | |
| BRPI0713447A2 (pt) | composição forma de dosagem oral sólida, e, método para o tratamento de dor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: THE WALTER AN ELIZA HALL INSTITUTE OF MEDICAL RESE |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |